COVID-19 Is Recurring In People Who Took Pfizer's Antiviral

New Post Public Reply Private Reply Replies (1) Message Board
Mauibound
329
COVID-19 Is Recurring In People Who Took Pfizer's Antiviral & Doctors Don't Know Why

Since the U.S. Food and Drug Administration (FDA) approved Paxlovid as a valid treatment for COVID-19 in December 2021, many people saw the benefits of using it. Many people report feeling better during the five-day course of treatment and, for a large group of people, that treatment is enough for them to be COVID-free. However, more and more cases of coronavirus rebound are cropping up in patients who completed their Paxlovid course successfully, only to see the virus come right back with symptoms when the treatment is over. As reported by NBC News, anecdotal reports of people who get sick again after taking Paxlovid are coming up every so often. This brings up some important questions: are those rebound patients safe to go out in public? Are they still infectious? Are they in any danger of hospitalization or seeing their symptoms worsen? Does this mean that Paxlovid is ineffective if it only suppresses the symptoms of the coronavirus during the treatment and not beyond?

In general, Paxlovid treatment has proven to be effective. In a clinical trial run by Pfizer between July and December 2021, unvaccinated patients treated with Paxlovid were 89% less likely to see their coronavirus infection develop into the serious stages that could lead to death. However, with some patients not only experiencing a return of their COVID-19 symptoms but also testing positive once more, some firm guidance is needed as to what to do with those cases. As of right now, there are no specific guidelines for rebound cases.


Rebound patients don't know where to turn to
Cryptographer/Shutterstock
NBC News described several cases of Paxlovid-treated patients developing coronavirus rebound infections in people ranging from a fully vaccinated and boosted 31-year-old to a 71-year-old man. In the case of the 31-year-old software engineer, Michael Henry, the patient found that when his COVID symptoms came back, he didn't know where to turn to. Every line of communication, including his doctor, his local COVID information line, and a health insurance nurse, provided him with different answers. This highlights how important it is for the CDC and/or the FDA to set up official guidelines in case these rebound cases continue to come up.


Dr. Michael Charness, the chief of staff at the VA Boston Healthcare System, detailed the case of one of his patients: a fully vaccinated and boosted 71-year-old man. The patient started taking Paxlovid from the day his symptoms started. The symptoms all but disappeared two days later and left him feeling good for a week, but once the course of medication ended, the man got sick again — this time for four days. According to testing, the man didn't develop a resistance to Paxlovid and he was not re-infected; it was the same coronavirus infection, re-emerging after the treatment had been completed.

New guidelines would be helpful
illpaxphotomatic/Shutterstock
As for now, neither Pfizer nor the CDC has presented any official guidelines on what to do with rebound cases of COVID. The reasons behind these cases are also still a subject of speculation. According to NBC News, Dr. Charness speculates that Paxlovid suppresses the symptoms of the coronavirus so well that the system's immune response is compromised. On the other hand, Dr. Timothy Brewer from the University of California believes that the coronavirus may be found in parts of the body that Paxlovid is unable to access, such as the blood-brain barrier. Once the treatment is ended, these remnants of the virus continue making the patient sick for a few more days before going away. Brewer also suggests that not everyone's absorption of Paxlovid will be as effective as expected, meaning that they just don't receive enough of the drug in order to be rid of the virus.


In those cases, using a longer treatment of Paxlovid could potentially be enough to finish the remaining virus cells. However, as it's not yet fully FDA-approved, doctors are unable to prescribe more Paxlovid at their own discretion. It seems that until this is addressed, the patients who experience rebound COVID may be stuck in limbo with little to no answers. At least the CDC has a COVID-19 quarantine calculator to help people determine how much longer they need to isolate.

https://www.slashgear.com/818151/times-techno...paign=clip

Todos Med Ltd. (TOMDF) Stock Research Links

TOMDF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Focus on Kidney Health in Blood Pressure Guidance

Updated Category News Views 3

Kicking Off the Conversation on Kidney Health The National Kidney Foundation (NKF) is sounding the alarm: it's time for kidney health to take center stage in the fight against high blood pressure. Fresh off the presses, the Kidney Disease Outcomes Quality Initiative (KDOQI) has thrown its hat into the ring by diving into the latest guidelines from the American Heart...

Continue Reading
MiniTool ShadowMaker 5.0: New Cloud Sync Feature

Updated Category News Views 0

Pushing the Boundaries with Cloud Sync Another day, another software upgrade. MiniTool ShadowMaker has jumped to version 5.0, throwing in a new Cloud Sync feature for Google Drive and OneDrive. Now, you might not be jumping out of your chair with excitement just yet, but hear me out. For those who fiddle with Windows backup and file sync often enough to owe Microsoft a...

Continue Reading
California Contractors Honored for Safety Commitment

Updated Category News Views 2

Commitment to Safety in the Construction Industry When it comes to construction, safety isn’t an afterthought—it’s woven into the very fabric of every project. The 39th Annual Construction Safety Excellence Awards by the Associated General Contractors of California (AGC of California) pits a spotlight on those embodying this ethos. Industry Leaders in Safety Held on...

Continue Reading
Vertice P2P Aims to Transform Procurement Efficiency

Updated Category News Views 9

Vertice Dives Deeper into the Procurement Game Grab a coffee and let's talk some procurement—one of the least sexy, yet utterly essential parts of any operation. Vertice's latest announcement is anything but mundane. They're spiraling deeper into the procurement universe with their new Procure-to-Pay (P2P) capability, a bold expansion from their Intake-to-Procure (I2P)...

Continue Reading
Procede Software Acquires RIMSS: Dealer Tech Shift?

Updated Category News Views 3

Procede's Big Play Seems like Procede Software is tossing the dice with its latest move. The software scene for dealership management is as cutthroat as a New York deli lineup, and now we've got Procede moving to scoop up RIMSS. This isn't just a back-office shuffle; it's a world-rocking maneuver that brings decades of dealer technology know-how into one basket. What's...

Continue Reading
Gillis Joins McGinnis Lochridge as COO Amid Firm's Milestone

Updated Category News Views 5

An Experienced Executor at the Helm Now, here's a story that rings of continuity meeting change. McGinnis Lochridge, a staple of the Texas legal scene since 1927, has tapped Charles Gillis to take charge as their Chief Operating Officer. You'd think they're gearing up to celebrate a hundred years by shaking things up internally. Why not bring in someone seasoned, I say?...

Continue Reading
Data Center Piping Surges With AI Cooling to $4.5B

Updated Category News Views 4

Liquid Cooling Revolutionizes Data Center Infrastructure Gotta hand it to the tech world, when it decides to shift, it shifts hard and fast. The data center piping market isn't just keeping up—it's sprinting. The move towards liquid-cooled AI setups isn’t just a trend; it’s a defining transformation. With a projected explosion to a $4.5 billion market by 2035, you...

Continue Reading
Local Visibility Crisis Looms for Small Businesses

Updated Category News Views 5

Scrolling through these fresh stats from BrightLocal's recent report, you can almost hear the alarm bells echoing across small towns and city squares. The data paints a surprisingly sobering picture: despite the fact that 71% of folks are heading straight to Google to find local businesses, only a mere 22% of small business owners are tagging it as one of their top tools...

Continue Reading
ImmunoForge Sets Sights on BIO-Europe 2026 for New Deals

Updated Category News Views 1

Making Waves with Cutting-Edge Drug Platforms Ah, how time flies in the biotech universe. Here we are, with ImmunoForge prepping to flaunt its high-tech gear at the big show in Cologne: BIO-Europe 2026. The company's aiming to gauge attention with its flashy ELP and LMT platforms, primed and ready for strategic partnerships. ELP: Revolutionizing Drug Delivery You've got...

Continue Reading
Cognizant AI Nexus Aims to Tame Enterprise AI Chaos

Updated Category News Views 5

AI Investments Without Returns: The Current Scenario Well, wouldn't you know it? Enterprises have sunk a fortune into AI, and they're wagging their fingers once more at the mounting bills with little to show for it. Play the investment game long enough, and it seems you'll find the numbers don't always rub together and make sparks. This familiar tune of over-budget...

Continue Reading

Top 5 Most Recently Viewed Articles

Embraer Expands Global Reach with C-390 Aircraft Sales

Updated Category News Views 309

Embraer's Milestone in Military Aircraft Sales Embraer, the renowned Brazilian aerospace manufacturer, has made significant strides in the military aviation sector. Recently, the company announced a contract for the sale of two C-390 Millennium military cargo aircraft to an undisclosed client. This exciting development is a testament to Embraer's commitment to providing...

Continue Reading
Welltower Sees Decrease in Short Interest: What It Means

Updated Category News Views 165

Welltower's Recent Trends in Short Interest Welltower (NYSE: WELL) has recently experienced a notable decrease in its short interest, with the percentage of shorted shares falling by 7.07% since the last report. With approximately 8.81 million shares sold short, this accounts for about 1.84% of the total available shares for trading. Based on current trading patterns, it...

Continue Reading
Rebuilding Strategies for a Resilient Los Angeles Infrastructure

Updated Category News Views 302

Urgent Call for Stronger Building Codes in Los Angeles Survivable and insurable homes are achievable for all LA County communities In the wake of recent wildfires that have shocked communities, experts are uniting to push for stringent building codes in Los Angeles. This response comes as residents grapple with the aftermath of destructive blazes that have significantly...

Continue Reading
Innovative AI Solutions Drive Business Growth and ROI

Updated Category News Views 212

Unleashing the Power of Conversational AI In today's fast-paced business landscape, leveraging technology effectively has never been more critical. Gupshup, a recognized leader in Conversational AI, has unveiled compelling results stemming from their partnership with Meta. The Total Economic Impact study illustrates the significant advantages that businesses can gain...

Continue Reading
iRhythm Technologies Unveils 2024 Sustainability Report

Updated Category News Views 146

iRhythm Technologies Unveils 2024 Sustainability Report iRhythm Technologies, Inc. (NASDAQ: IRTC), a pioneering digital health care company, has taken a significant step by releasing its 2024 Corporate Sustainability Report. This document serves as a testament to the company’s ongoing dedication to fostering a culture that prioritizes quality and sustainability in...

Continue Reading